Kanuma (Sebelipase Alfa) Injection

Kanuma (sebelipase alfa), from Alexion Pharmaceuticals (AstraZeneca Rare Disease), is indicated for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D), including infantile-onset (Wolman disease) and later-onset forms.

LAL-D is caused by a deficiency of the lysosomal acid lipase enzyme, leading to abnormal buildup of fats (cholesteryl esters and triglycerides) in cells of the liver, spleen, and other organs. Sebelipase alfa is a recombinant form of this enzyme, replacing the missing/deficient enzyme to help break down the accumulated lipids.

• Hypersensitivity reactions, including anaphylaxis, have occurred; infusions should be given where such reactions can be managed, with pre-medication as needed.
• Infusion-associated reactions are common, particularly in infants.
• Common side effects: fever, diarrhea, vomiting, rhinitis, anemia, cough, upper respiratory tract infection.

What documents are required to import Kanuma to India?

Kanuma may be imported in the patient’s name only, by patients or government hospitals. The following documentation is required:

• A valid prescription from a registered physician/geneticist
• Diagnostic/enzyme assay report confirming LAL-D
• Patient ID proof (issued by the Government of India)

How is the order confirmed?

The order is confirmed only after receipt and verification of a valid prescription and an import permit, if applicable.

Is Kanuma available in India?

Kanuma is not commercially marketed in India. It can be legally accessed through the Named Patient Program (NPP).

Indian Pharma Network (IPN) can source Kanuma from Alexion’s authorized distribution network and facilitate supply to patients, doctors, and hospitals. Kanuma requires cold-chain handling (refrigerated 2-8°C); IPN uses temperature-monitored logistics for every shipment.

For Kanuma cost in India and availability, contact IPN at Phone: +91-9310090915 or email info@indianpharmanetwork.in.

Global Approval Status:

• United States: Approved by the FDA — December 2015.

What is Kanuma used for?

Kanuma is an enzyme replacement therapy for Lysosomal Acid Lipase Deficiency (LAL-D), including infantile-onset Wolman disease.

Who manufactures Kanuma?

Kanuma is manufactured by Alexion Pharmaceuticals (part of AstraZeneca’s Rare Disease group).

How is Kanuma administered?

As an intravenous infusion, with dosing frequency and amount individualized based on age and disease severity.

How much does Kanuma cost in India?

Cost depends on body-weight dosing and sourcing logistics — share your prescription with IPN for a quote.